Total Payments
$1,900
2024 Payments
$792.82
Companies
21
Transactions
64
Medicare Patients
6,897
Medicare Billing
$5.3M
Payment Breakdown by Category
Food & Beverage$1,717 (90.4%)
Education$167.54 (8.8%)
Other$15.38 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,717 | 59 | 90.4% |
| Education | $167.54 | 4 | 8.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15.38 | 1 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $501.74 | 7 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $235.43 | 18 | $0 (2019) |
| UCB, Inc. | $224.02 | 6 | $0 (2024) |
| Lundbeck LLC | $220.79 | 5 | $0 (2024) |
| ARGENX US, INC. | $218.26 | 3 | $0 (2024) |
| Averitas Pharma Inc. | $113.03 | 3 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $68.64 | 5 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $61.81 | 2 | $0 (2024) |
| Amgen Inc. | $41.85 | 2 | $0 (2024) |
| GENZYME CORPORATION | $32.41 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $792.82 | 20 | Lundbeck LLC ($220.79) |
| 2023 | $453.67 | 6 | Alexion Pharmaceuticals, Inc. ($228.90) |
| 2021 | $121.84 | 1 | Alexion Pharmaceuticals, Inc. ($121.84) |
| 2019 | $152.22 | 13 | Supernus Pharmaceuticals, Inc. ($135.01) |
| 2018 | $63.54 | 4 | Supernus Pharmaceuticals, Inc. ($63.54) |
| 2017 | $315.92 | 20 | Sunovion Pharmaceuticals Inc. ($68.64) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Education | In-kind items and services | $75.00 | General |
| Category: Rare Disease | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $32.28 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Education | In-kind items and services | $75.00 | General |
| Category: Rare Disease | ||||||
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Education | In-kind items and services | $1.00 | General |
| Category: Rare Disease | ||||||
| 10/31/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $20.94 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $124.46 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/24/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/15/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Immunology | ||||||
| 09/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $29.53 | General |
| Category: IMMUNOLOGY | ||||||
| 08/29/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $16.50 | General |
| Category: NEUROLOGY | ||||||
| 08/14/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $33.90 | General |
| Category: PAIN MANAGEMENT | ||||||
| 06/21/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $25.48 | General |
| Category: NEUROLOGY | ||||||
| 06/07/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Neurology | ||||||
| 05/17/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $124.46 | General |
| Category: Neurology | ||||||
| 05/09/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $33.41 | General |
| Category: NEUROLOGY | ||||||
| 05/01/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $47.62 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/11/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Neurology | ||||||
| 02/15/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $29.82 | General |
| Category: Neurology | ||||||
| 01/11/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: Neurology | ||||||
| 12/01/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $31.51 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/26/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $123.54 | General |
| Category: Rare Disease | ||||||
| 10/23/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $105.51 | General |
| Category: Immunology | ||||||
| 10/02/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $88.82 | General |
| 07/06/2023 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Education | In-kind items and services | $16.54 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 1,777 | 64,742 | $5.6M | $1.5M |
| 2022 | 28 | 1,398 | 65,227 | $4.4M | $1.4M |
| 2021 | 29 | 1,687 | 72,639 | $5.4M | $1.4M |
| 2020 | 36 | 2,035 | 59,215 | $3.8M | $992,022 |
Total Patients
6,897
Total Services
261,823
Medicare Billing
$5.3M
Procedure Codes
129
All Medicare Procedures & Services
129 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 20 | 31,780 | $4.4M | $1.2M | 26.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 33 | 30,100 | $541,800 | $148,405 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 279 | 339 | $98,649 | $30,577 | 31.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 126 | 159 | $67,575 | $21,235 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 96 | 96 | $58,944 | $14,535 | 24.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 156 | 185 | $42,550 | $13,015 | 30.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 96 | 96 | $46,464 | $11,630 | 25.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 26 | 231 | $43,197 | $10,740 | 24.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 23 | 546 | $31,668 | $8,364 | 26.4% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 65 | 65 | $30,810 | $7,660 | 24.9% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 47 | 47 | $26,790 | $6,961 | 26.0% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 63 | 64 | $21,696 | $5,634 | 26.0% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 78 | 98 | $14,406 | $4,493 | 31.2% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2023 | 15 | 36 | $22,716 | $4,321 | 19.0% |
| 95887 | Needle measurement of electrical activity in trunk or head muscles | Office | 2023 | 63 | 63 | $12,600 | $3,981 | 31.6% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 21 | 21 | $13,461 | $3,871 | 28.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 58 | 59 | $11,126 | $3,806 | 34.2% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 24 | 64 | $12,872 | $3,571 | 27.7% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 16 | 16 | $13,168 | $3,087 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 20 | $8,500 | $2,070 | 24.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $6,479 | $1,586 | 24.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 118 | 175 | $3,850 | $1,470 | 38.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 18 | 46 | $3,312 | $1,136 | 34.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 13 | 41 | $2,952 | $921.96 | 31.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 45 | 87 | $3,828 | $900.45 | 23.5% |
About Dr. Karrie Grear, MD
Dr. Karrie Grear, MD is a Neurology healthcare provider based in Wilmington, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2010. The National Provider Identifier (NPI) number assigned to this provider is 1063733517.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Karrie Grear, MD has received a total of $1,900 in payments from pharmaceutical and medical device companies, with $792.82 received in 2024. These payments were reported across 64 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,717).
As a Medicare-enrolled provider, Grear has provided services to 6,897 Medicare beneficiaries, totaling 261,823 services with total Medicare billing of $5.3M. Data is available for 4 years (2020–2023), covering 129 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Wilmington, NC
- Active Since 06/18/2010
- Last Updated 05/26/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1063733517
Products in Payments
- ULTOMIRIS (Biological) $274.54
- VYEPTI (Biological) $220.79
- VYVGART (Drug) $218.26
- Rystiggo (Drug) $197.45
- TROKENDI XR (Drug) $181.24
- Soliris (Drug) $121.84
- QUTENZA (Drug) $113.03
- APTIOM (Drug) $68.64
- HYQVIA (Biological) $61.81
- OXTELLAR XR (Drug) $54.19
- UPLIZNA (Biological) $41.85
- AUBAGIO (Drug) $32.41
- Rebif (Biological) $25.82
- ONZETRA Xsail (Drug) $20.98
- STELARA (Biological) $20.08
- GILENYA (Drug) $18.57
- ONPATTRO (Drug) $17.21
- SOLIRIS (Biological) $16.54
- NUPLAZID (Drug) $16.01
- AMPYRA (Drug) $15.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Wilmington
Dr. Johny Ardeljan, Do, DO
Neurology — Payments: $10,389
Neurology $10,389
Alfred De Maria, Md, MD
Neurology — Payments: $7,542
Neurology $7,542
Panida Piboolnurak, Md, MD
Neurology — Payments: $5,344
Neurology $5,344
Dr. Badal Jain, Md, MD
Neurology — Payments: $1,273
Neurology $1,273
William Boles, Md, MD
Neurology — Payments: $1,106
Neurology $1,106
Angelique Manasseh, Do, DO
Neurology — Payments: $679.94
Neurology $679.94